As research continues to uncover the full potential of GLP-1 receptor agonists, their role in modern medicine is likely to expand, providing even more opportunities for improving patient outcomes
The FDA is currently reviewing high-dose oral semaglutide, and a decision from the drug administration could make this new option available to patients by late 2025
Using paired peripheral-blood methylomes collected at baseline and 32 weeks for placebo and semaglutide groups, we conducted a post hoc analysis spanning 17 first-, second-, and third-generation DNA-methylation clocks
Anh, N.H., Kim, S.J., Long, N.P., Min, J.E., Yoon, Y.C., Lee, E.G., Kim, M., Kim, T.J., Yang, Y.Y., Son, E.Y., Yoon, S.J., Diem, N.C., Kim, H.M